CDR-404 by CDR-Life for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

CDR-404 is under clinical development by CDR-Life and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Colorado road conditions: Heavy snow freezes traffic across Colorado, CDOT barring trailers from I-70 in mountains – The Cannabist

A winter storm could stifle travel across Colorado today and Saturday, closing roadways and threatening to make driving difficult or impossible on segments of interstates

November 8, 2024

FDA committee unanimously backs Lilly’s donanemab bid for Alzheimer’s – Pharmaceutical Technology

Donanemab is a monoclonal antibody designed to ablate amyloid plaques that aggregate in patients with Alzheimer’s disease. Credit: Tada Images/Shutterstock.com Despite being delayed twice, the

June 10, 2024

Study shows high rates of unrecognized heart valve disease in healthy seniors

The sheer scale of undiagnosed heart valve disease in our ageing population has been revealed for the first time, thanks to new research led by

June 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.